Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The ...
Dr. Kai Pinkernell, M.D., Managing Director, Science & Innovation at Dr. Falk Pharma, added, “The completion of enrollment is a significant milestone in our partnership, reflecting the strength of ...
Article ‘Count’ and ‘Share’ for Dr. Falk Pharma GmbH based on listed parameters only. The articles listed below published by authors from Dr. Falk Pharma GmbH, organized by journal and article, ...
Merck Signs Agreement with Dr. Falk PharmaGmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody Merck (NYSE: MRK), ...
ROSCREA, Ireland and FREIBURG, Germany, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (“Renexxion”), a private biopharmaceutical company committed to delivering innovative drugs to ...
The positions in the table below reflect the Dr. Falk Pharma GmbH's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the ...
Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is currently no approved medicine to treat primary sclerosing cholangitis. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results